CellCarta and Pillar Biosciences Accelerate FGFR NGS Assay from RUO to IUO for Global Phase 3 Oncology Trial
Integrated collaboration completed clinical trial assay development and validation and enabled IDE and associated regulatory submissions in approximately five to six months. MONTREAL, CANADA, – June 23, 2026 – CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced the successful development and clinical implementation of a customized FGFR next-generation sequencing assay in collaboration […]